Skip to main content
EWTX
NASDAQ Life Sciences

Edgewise Therapeutics Sells Neuromuscular Program for $1.55B Upfront, Pivots to Cardiovascular Focus

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$43.15
Mkt Cap
$3.675B
52W Low
$12.15
52W High
$39.96
52W Position info
255% above low
Off High info
at 52W high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

EWTX has more than doubled off its 52-week low of $12.15.

Summary

Edgewise Therapeutics has officially sold its neuromuscular drug program, including sevasemten, to Servier for $1.55 billion upfront and up to $1.1 billion in milestones, allowing the company to pivot its strategic focus to its cardiovascular pipeline with enhanced financial strength.


Key Events · M&A and Partnerships · EWTX

  • Sale of Neuromuscular Program

    Edgewise Therapeutics entered into an agreement to sell its sevasemten compound and neuromuscular program to Servier Pharmaceuticals LLC and Les Laboratoires Servier.

  • Significant Upfront Cash

    The transaction includes $1.55 billion in upfront cash consideration, payable at closing.

  • Potential Milestone Payments

    Edgewise is eligible for up to an additional $1.1 billion in regulatory and commercial milestone payments.

  • Strategic Pivot to Cardiovascular

    The company will now focus exclusively on its cardiovascular pipeline, including EDG-7500 for hypertrophic cardiomyopathy and EDG-15400 for HFpEF.


Analysis · EWTX · Life Sciences

This 8-K formalizes the sale of Edgewise Therapeutics' sevasemten compound and entire neuromuscular program to Servier for $1.55 billion in upfront cash, with potential for an additional $1.1 billion in milestone payments. This transformational deal provides substantial capital, significantly strengthening the company's balance sheet and enabling it to fully fund its lead cardiovascular program, EDG-7500, through potential approval. The company will now focus entirely on its cardiovascular pipeline, representing a major strategic pivot that has been met with strong market approval, as evidenced by the stock trading above its 52-week high.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 52.1% of the 217 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EWTX was trading at $43.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $12.15 to $39.96. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EWTX - Latest Insights

EWTX
Nov 06, 2026, 11:47 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $43.18
Real-time Price: $47.57 info
Change: +$4.40 (+10%) info
Market Cap: $5.208B info
EWTX
Nov 04, 2026, 4:01 PM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $37.51
Real-time Price: $47.57 info
Change: +$10.06 (+27%) info
Market Cap: $5.208B info
EWTX
Aug 06, 2026, 8:05 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $44.95
Real-time Price: $47.57 info
Change: +$2.62 (+6%) info
Market Cap: $5.208B info
EWTX
Aug 06, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $44.95
Real-time Price: $47.57 info
Change: +$2.62 (+6%) info
Market Cap: $5.208B info
EWTX
Jul 16, 2026, 8:01 AM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $39.23
Real-time Price: $47.57 info
Change: +$8.34 (+21%) info
Market Cap: $5.208B info